share_log

Baolingbao BiologyLtd (SZSE:002286) Strong Profits May Be Masking Some Underlying Issues

Baolingbao BiologyLtd (SZSE:002286) Strong Profits May Be Masking Some Underlying Issues

宝磊宝生物股份有限公司(SZSE:002286)强劲利润可能掩盖了一些潜在问题
Simply Wall St ·  2024/11/05 18:04

Baolingbao Biology Co.,Ltd.'s (SZSE:002286) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being concerned with what they see.

保龄宝生物股份有限公司(SZSE:002286)最近强劲的收益并没有对股价产生太大的影响。我们认为这是因为投资者在关注除法定利润外的内容时感到担忧。

big
SZSE:002286 Earnings and Revenue History November 5th 2024
SZSE:002286 每股收益和营业收入历史数据 2024年11月5日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Baolingbao BiologyLtd's profit received a boost of CN¥28m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Baolingbao BiologyLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我们的数据显示,保龄宝生物有限公司的利润在过去一年中因飞凡项目获得了2800万人民币的提振。虽然获得更高的利润总是令人高兴的,但飞凡项目的大幅贡献有时会降低我们的热情。当我们分析全球绝大多数上市公司时,我们发现重大的飞凡项目通常不会重复。这也是预料之中的,因为这些增长被描述为“飞凡”。如果保龄宝生物公司无法再次获得这种贡献,那么其他条件不变,我们预计其利润在当前年度将会下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Baolingbao BiologyLtd.

注意:我们始终建议投资者检查资产负债表的实力。请点击此处查看我们对保龄宝生物公司资产负债表分析。

Our Take On Baolingbao BiologyLtd's Profit Performance

我们对保龄宝生物公司的利润表现看法

We'd posit that Baolingbao BiologyLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Baolingbao BiologyLtd's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 40% EPS growth in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 2 warning signs for Baolingbao BiologyLtd and you'll want to know about these bad boys.

我们认为,由于存在较大的飞凡项目,保龄宝生物有限公司的红利并不是对持续生产力的清晰体现。因此,我们认为保龄宝生物有限公司的红利利润可能比其潜在盈利能力更好。但至少持有者可以从过去一年40%的每股收益增长中获得一些安慰。当然,在分析其收益时我们只是触及到了表面;人们也可以考虑利润率、预测增长和投资回报率等其他因素。需要注意的是,在分析股票时,值得注意所涉及的风险。您可能会感兴趣,我们发现了2个关于保龄宝生物有限公司的警告信号,您可能想要了解这些信息。

This note has only looked at a single factor that sheds light on the nature of Baolingbao BiologyLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

这份报告仅研究了一个能揭示保龄宝生物有限公司利润性质的因素。但如果您能集中注意力于细枝末节,总有更多发现。有些人认为股本回报率高是优质企业的一个良好迹象。因此,您可能希望查看这里企业的股本回报率高的免费集合,或者这份股东持股高的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发